<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>From tryptophan-based amides to tertiary amines</dc:title><dc:creator>Meden,	Anže	(Avtor)
	</dc:creator><dc:creator>Knez,	Damijan	(Avtor)
	</dc:creator><dc:creator>Brazzolotto,	Xavier	(Avtor)
	</dc:creator><dc:creator>Nachon,	Florian	(Avtor)
	</dc:creator><dc:creator>Dias,	José	(Avtor)
	</dc:creator><dc:creator>Svete,	Jurij	(Avtor)
	</dc:creator><dc:creator>Stojan,	Jure	(Avtor)
	</dc:creator><dc:creator>Grošelj,	Uroš	(Avtor)
	</dc:creator><dc:creator>Gobec,	Stanislav	(Avtor)
	</dc:creator><dc:subject>cholinesterase inhibitors</dc:subject><dc:subject>Alzheimer's disease</dc:subject><dc:subject>butyrylcholinesterase</dc:subject><dc:subject>carbamate</dc:subject><dc:subject>pseudoirreversible inhibition</dc:subject><dc:description>Lead optimization of a series of tryptophan-based nanomolar butyrylcholinesterase (BChE) inhibitors led to tertiary amines as highly potent, achiral, sp$^3$-rich analogues with better synthetic accessibility and high selectivity over acetylcholinesterase (one to ten thousandfold). Taking it one step further, the introduction of a carbamate warhead on the well-explored reversible scaffold allowed conversion to pseudoirreversible inhibitors that bound covalently to BChE and prolonged the duration of inhibition (half-life of 14.8 h for compound 45a-carbamoylated enzyme). Additionally, N-hydroxyindole was discovered as a novel leaving group chemotype. The covalent mechanism of action was confirmed by time-dependency experiments, progress curve analysis, and indirectly by co-crystallization with the human recombinant enzyme. Two crystal structures of BChE-inhibitor complexes were solved and coupled with the supporting molecular dynamics simulations increased our understanding of the structure-activity relationship, while also providing the neccessary structural infromation for future optimization of this series. Overall, this research demonstates the high versatility and potential of this series of BChE inhibitors.</dc:description><dc:date>2022</dc:date><dc:date>2022-09-09 10:39:16</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>140000</dc:identifier><dc:identifier>UDK: 615.4:54:616.894</dc:identifier><dc:identifier>ISSN pri članku: 0223-5234</dc:identifier><dc:identifier>DOI: 10.1016/j.ejmech.2022.114248</dc:identifier><dc:identifier>COBISS_ID: 100613379</dc:identifier><dc:language>sl</dc:language></metadata>
